Literature DB >> 9112968

Botulinum toxin A in the hemiplegic upper limb: a double-blind trial.

I S Corry1, A P Cosgrove, E G Walsh, D McClean, H K Graham.   

Abstract

In a randomised, double-blind study, the effects of intramuscular injection of botulinum toxin type A (BtA) into the upper limb were compared with those of normal saline solution in 14 patients with cerebral palsy; their mean age was 9 years. Range of movement and function were assessed before injection and at 2 and 12 weeks after injection. BtA injection significantly increased maximum active elbow and thumb extension and significantly reduced tone at wrist and elbow. The hand grasp-and-release score improved, representing a modest functional change, but fine motor function, assessed by the ability to pick up coins, did not improve and in some cases deteriorated temporarily. The most notable subjective change was the cosmetic benefit of reduced involuntary elbow flexion. The tone-reducing effect of BtA was clinically detectable in comparison with the placebo and patients and parents perceived the change as beneficial. The median of changes in the treatment group was small but the range was large, suggesting that BtA can be useful in selected patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9112968     DOI: 10.1111/j.1469-8749.1997.tb07408.x

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  24 in total

1.  The use of botulinum toxin in paediatric hypertonia.

Authors:  Darcy Fehlings
Journal:  Paediatr Child Health       Date:  2005-09       Impact factor: 2.253

2.  Localization of motor entry points and terminal intramuscular nerve endings of the musculocutaneous nerve to biceps and brachialis muscles.

Authors:  Je-Hun Lee; Hye-Won Kim; Sun Im; Xiaochun An; Mi-Sun Lee; U-Young Lee; Seung-Ho Han
Journal:  Surg Radiol Anat       Date:  2009-09-25       Impact factor: 1.246

Review 3.  Treatment of Disorders of Tone and Other Considerations in Pediatric Movement Disorders.

Authors:  Stephen R Deputy; Ann H Tilton
Journal:  Neurotherapeutics       Date:  2021-01-06       Impact factor: 7.620

4.  Upper limb motion analysis in children with hemiplegic cerebral palsy: proximal kinematic changes after distal botulinum toxin or surgical treatments.

Authors:  Frank Fitoussi; Amadou Diop; Nathalie Maurel; El Mostefa Laasel; Brice Ilharreborde; Georges François Penneçot
Journal:  J Child Orthop       Date:  2011-09-03       Impact factor: 1.548

Review 5.  Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence.

Authors:  Marissa Barlaan Lukban; Raymond L Rosales; Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2009-01-14       Impact factor: 3.575

6.  Botulinum toxin use as an adjunctive modality in a patient with multiple flexor tendon ruptures.

Authors:  Wade D Kubat; Mark Rekant
Journal:  Hand (N Y)       Date:  2008-03-14

Review 7.  Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE).

Authors:  Brian J Hoare; Margaret A Wallen; Christine Imms; Elmer Villanueva; Hyam Barry Rawicki; Leeanne Carey
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

8.  Botulinum Toxin Treatment on Upper Limb Function in School Age Children With Bilateral Spastic Cerebral Palsy: One Year Follow-up.

Authors:  Jee Sun Lee; Kyu Bum Lee; Yu Ryun Lee; You Nam Choi; Chul Woo Park; Sang Duck Park; Dong Hwa Jung; Chul Sang Lee
Journal:  Ann Rehabil Med       Date:  2013-06-30

Review 9.  Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin.

Authors:  L Andrew Koman; Beth Paterson Smith; Rajesh Balkrishnan
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

10.  Muscle weakness and lack of reflex gain adaptation predominate during post-stroke posture control of the wrist.

Authors:  Carel G M Meskers; Alfred C Schouten; Jurriaan H de Groot; Erwin de Vlugt; Bob J J van Hilten; Frans C T van der Helm; Hans J H Arendzen
Journal:  J Neuroeng Rehabil       Date:  2009-07-23       Impact factor: 4.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.